» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More Information on Drug Promotion

More information on rosuvastatin (Crestor)

Letter Urging Action on AstraZeneca's Misleading Crestor Advertising

November 24, 2004

Lester Crawford, DVM, Acting Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, MD  20854

Dear Dr. Crawford,

I am writing to you to urge you to force AstraZeneca to immediately stop a false and misleading advertising campaign in which the company is claiming that there is no FDA concern about the safety of Crestor, its heavily advertised cholesterol-lowering drug.

In March of this year, Public Citizen’s Health Research Group petitioned the FDA to ban Crestor (rosuvastatin) because the dual safety issues of its unique kidney-damaging properties and because it appears to have a higher rate of the life-threatening breakdown of muscle, rhabdomyolysis, than the other statins now on the market.

Last week, the Acting Director of FDA’s Center for Drug Evaluation and Research (CDER), Dr. Steven Galson, was quoted as saying that the agency "has been very concerned about Crestor since the day it was approved, and we've been watching it very carefully." He said the agency is "concerned about the same issues with Crestor as Public Citizen."[1]

In large newspaper advertisements running this week and on its Web site — in response to Crestor being identified by an FDA Drug Safety official, Dr. David Graham at a Senate hearing on November 18th as one of five currently marketed drugs about which there were safety concerns — AstraZeneca has made false and or misleading statements about the FDA’s current opinion about Crestor:

The Web site states that “AstraZeneca has followed up these remarks with speed and diligence.   We have been assured today at senior levels in the FDA that there is no concern in relation to CRESTOR’s safety.”[2] In an advertisement, referring to the opinions of FDA scientists, the company stated that “the concerns that have been raised [by Dr. Graham about Crestor] have no medical or scientific basis.”[3]

This statement constitutes false and or misleading advertising that violates FDA laws and regulations since it clearly misrepresents the statements of the FDA’s top drug official, Dr. Galson, and, certainly, many other FDA officials. I urge that the FDA immediately stop AstraZeneca from running this or any other misleading advertising about Crestor.


Sidney M. Wolfe, M.D.
Public Citizen's Health Research Group

[1] Washington Post, November 18, 2004.

[2] AstraZeneca web site, accessed November 24, 2004. Now available at:

[3] New York Times, November 24, 2004, page A15.

Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.